Product image of Minulet (Ethinylestradiol, Gestodene) supplied by GNH India

Minulet

Active Ingredient:
Ethinylestradiol, Gestodene
Origin:
EU

Minulet (Ethinylestradiol, Gestodene)

Ethinylestradiol, the active ingredient in Minulet, is a combined oral contraceptive presented as an oral tablet for oral use. Together with gestodene, it combines a synthetic estrogen and a progestogenic agent to provide reliable contraception and cycle control for women of reproductive age. GNH India supplies Minulet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and procurement teams worldwide.

Manufacturer / TM Owner

Pfizer S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Minulet, a combined oral contraceptive, is used within the hormonal birth‑control pathway to prevent pregnancy.
  • Pregnancy prevention: provides reliable contraception for women of childbearing potential.
  • Menstrual cycle regulation: helps stabilize cycle length and reduce irregular bleeding.
  • Acne management: can improve moderate hormonal acne in some patients.

How It Works

  • Minulet works by delivering ethinylestradiol and gestodene, which together suppress the hypothalamic‑pituitary‑ovarian axis. The estrogen component inhibits the mid‑cycle surge of luteinizing hormone (LH) and follicle‑stimulating hormone (FSH), preventing ovulation. Gestodene thickens cervical mucus and induces endometrial changes that reduce the likelihood of implantation, thereby providing contraceptive efficacy.

Side Effects

Common Side Effects

  • Nausea: mild to moderate stomach upset.
  • Headache: tension‑type or migraine‑like.
  • Breast tenderness: transient swelling or discomfort.
  • Spotting: irregular breakthrough bleeding.
  • Weight gain: modest fluid retention.
  • Mood changes: irritability or emotional fluctuations.

Serious or Rare Side Effects

  • Deep vein thrombosis: blood clot formation in deep veins.
  • Pulmonary embolism: clot migration to lung vessels.
  • Stroke: cerebrovascular accident, especially in high‑risk individuals.
  • Myocardial infarction: heart attack risk in susceptible patients.
  • Severe allergic reaction: anaphylaxis, rash, or angioedema.
  • Liver dysfunction: jaundice or abnormal liver enzymes.

Precautions & Warnings

Before prescribing Minulet, clinicians should evaluate individual risk factors and counsel patients on safe use.

  • Assess thrombotic risk: review personal and family history of clotting disorders.
  • Screen for hypertension: monitor blood pressure regularly.
  • Evaluate liver function: avoid use in active liver disease.
  • Counsel on smoking: advise cessation, especially in women over 35.
  • Review medication history: identify potential interacting drugs.
  • Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Avoid Interactions

Minulet may interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

  • Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): reduce contraceptive efficacy.
  • Rifampin and other potent antibiotics: may lower hormone levels.
  • Protease inhibitor antiretrovirals: can alter metabolism of estrogen.
  • St. John’s wort: herbal inducer that decreases effectiveness.
  • Certain antifungal agents (e.g., griseofulvin): may diminish hormone concentrations.

Moderate Interactions (Monitor Closely)

  • Azole antifungals (e.g., fluconazole): may increase hormone exposure.
  • Macrolide antibiotics (e.g., erythromycin): potential modest effect on levels.
  • Diuretics: may affect fluid balance and blood pressure.
  • Antihypertensives: monitor for additive blood pressure changes.
  • Antidepressants (SSRIs): watch for mood‑related side effects.

Frequently Asked Questions

Minulet is a combined oral contraceptive indicated for the prevention of pregnancy in women of reproductive age. It may also be prescribed to help regulate menstrual cycles and to manage moderate hormonal acne.

The ethinylestradiol component suppresses the mid‑cycle surge of luteinizing hormone and follicle‑stimulating hormone, preventing ovulation. Gestodene thickens cervical mucus and alters the endometrial lining, making it less suitable for implantation, thereby providing contraceptive protection.

The dosing regimen for Minulet is determined by the prescribing clinician. Typically, it is taken as a daily oral tablet following the specific cycle schedule outlined in the prescription, but the exact regimen should be confirmed with a healthcare professional.

Minulet is intended for use only when pregnancy is not desired. It should not be started during pregnancy, and if pregnancy occurs, the product should be discontinued. Safety during breastfeeding is not established; women should consult their physician before using any hormonal contraceptive while nursing.

To order Minulet, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Minulet contains ethinylestradiol and gestodene, a low‑dose progestogen that offers a favorable bleeding profile and lower androgenic activity compared with some older formulations. Its efficacy and safety are comparable to other second‑generation combined oral contraceptives, but individual tolerability may vary.

Minulet tablets should be stored at ambient temperature, below 25 °C, in the original blister pack to protect from moisture and light. Keep the medication out of reach of children and do not use after the expiration date.

Minulet is taken orally, usually once daily at the same time each day. Patients follow a 21‑day active tablet regimen followed by a 7‑day placebo or hormone‑free interval, as directed by their prescriber.

Serious risks include thromboembolic events such as deep vein thrombosis, pulmonary embolism, stroke, and myocardial infarction, especially in women with pre‑existing risk factors. Rare but severe allergic reactions and liver dysfunction may also occur.

Minulet is contraindicated in women with a history of thromboembolic disorders, uncontrolled hypertension, active liver disease, known or suspected breast cancer, or those who are pregnant. Smoking women over 35 years of age should avoid its use due to increased cardiovascular risk.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ethinylestradiol, Gestodene

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT